Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Gross Margin (2016 - 2025)

Historic Gross Margin for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to 7.89%.

  • China Pharma Holdings' Gross Margin rose 393500.0% to 7.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.93%, marking a year-over-year increase of 234100.0%. This contributed to the annual value of 43.84% for FY2024, which is 398300.0% down from last year.
  • China Pharma Holdings' Gross Margin amounted to 7.89% in Q3 2025, which was up 393500.0% from 8.48% recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Gross Margin ranged from a high of 11.56% in Q1 2021 and a low of 109.78% during Q2 2024
  • Moreover, its 5-year median value for Gross Margin was 10.56% (2022), whereas its average is 13.79%.
  • Per our database at Business Quant, China Pharma Holdings' Gross Margin plummeted by -964200bps in 2024 and then soared by 1013000bps in 2025.
  • Over the past 5 years, China Pharma Holdings' Gross Margin (Quarter) stood at 10.45% in 2021, then tumbled by -86bps to 1.46% in 2022, then tumbled by -352bps to 3.68% in 2023, then plummeted by -285bps to 14.16% in 2024, then skyrocketed by 44bps to 7.89% in 2025.
  • Its Gross Margin stands at 7.89% for Q3 2025, versus 8.48% for Q2 2025 and 11.97% for Q1 2025.